COVID-19 update: Neopterin monoclonal antibody available at orders@selectiveantibodies.com
It has met this overall target by developing new technology that can be applied across the board - from high throughput analysers to very simple to use point of need applications.
The company was formed from a dynamic team of enthusiasts in the specialist areas required, from chemistry to antibody production and immunoassay design.
Our focus is the development of highly accurate dipsticks that are extremely simple to use, read and understand.
Professor Colin Self, Founder and Chief Executive